ViGeneron GmbH
ViGeneron announces closing of series A financing to drive development of next generation gene therapy pipeline
DGAP-News: ViGeneron GmbH
/ Key word(s): Financing
ViGeneron announces closing of series A financing to drive development of next generation gene therapy pipeline – Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms – Round attracts two esteemed investors – WuXi AppTec and Sequoia Capital China known for investing in cutting-edge technologies and tomorrow’s treatments and cures for patients in needs Munich, Germany, November 28, 2019 – ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China. The proceeds will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs. ViGeneron’s pipeline in gene therapy addresses ophthalmic diseases with high unmet medical need, including two programs in development for undisclosed indications where no approved treatment options are currently available. The company’s two novel next-generation gene therapy platforms are geared towards addressing the limitations of existing adeno-associated virus (AAV)-based gene therapies. The vgAAV vector platform, based on novel engineered AAV capsids, enables a superior transduction of target cells and is designed to efficiently cross biological barriers. These attributes allow vgAAV vectors to target a broad spectrum of cell types in the retina and potentially other tissues, such as central nervous system tissue; enabling intravitreal, less invasive treatment administration. For larger genes (>5Kb) the company has developed the innovative REVeRT vector platform. This platform uses an innovative vector approach to pack split genes into individual vgAAV vectors and generate a full-length protein via mRNA trans-splicing. ViGeneron is a spin-off of the Ludwig-Maximilians-University (LMU) in Munich. The company’s founding team includes highly experienced executives and internationally renowned experts with track records in developing retinal gene therapy programs from discovery to clinical stage: Dr. Caroline Man Xu (Co-founder and CEO), Prof. Dr. Martin Biel (Scientific Co-founder), and Prof. Dr. Stylianos Michalakis (Scientific Co-founder). Dr. Caroline Man Xu, Co-founder and CEO of ViGeneron said: “The evolution of medicines from small molecules to proteins has driven increased therapeutic benefits in the past; the next generation of gene therapies holds tremendous promise for patients. We are passionate about bringing innovations to patients. This financing is an important validation of our next-generation gene therapy technology platforms and ophthalmic development programs. With these top-tier investors and a strong ophthalmologic network supporting us, we are now in an excellent position to accelerate our development programs.” Edward Hu, Co-CEO of WuXi AppTec, commented: “We are impressed by ViGeneron’s vgAAV vector platform and the innovative REVeRT vector platform. These gene therapy platform technologies will potentially generate superior gene therapy products to treat a wide range of diseases that are traditionally difficult to treat. We look forward to supporting the company to deliver on its great promises for the patients in need.” About ViGeneron About WuXi AppTec About Sequoia Capital China Contact: Media and Investor Relations:
28.11.2019 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. |